[INDIRECT FIBRINOLYTIC AND ANTICOAGULANT TREATMENT OF THROMBOSIS].
D000925:Anticoagulants; D001162:Arteriosclerosis Obliterans; D001167:Arteritis; D003327:Coronary Disease; D003925:Diabetic Angiopathies; D005017:Ethyl Biscoumacetate; D005853:Geriatrics; D006801:Humans; D006973:Hypertension; D007294:Inositol; D007383:Intermittent Claudication; D020766:Intracranial Embolism; D002542:Intracranial Embolism and Thrombosis; D009525:Niacin; D011928:Raynaud Disease; D013919:Thromboangiitis Obliterans; D013923:Thromboembolism; D013924:Thrombophlebitis; D013927:Thrombosis; D014665:Vasodilator Agents
D000925:Anticoagulants; D014665:Vasodilator Agents; D005017:Ethyl Biscoumacetate; D009525:Niacin; D007294:Inositol
ARTERIOSCLEROSIS OBLITERANS; ARTERITIS; CEREBRAL EMBOLISM AND THROMBOSIS; CORONARY DISEASE; DIABETIC ANGIOPATHIES; ETHYL BISCOUMACETATE; GERIATRICS; HYPERTENSION; INOSITOL; INTERMITTENT CLAUDICATION; NICOTINIC ACID; RAYNAUD'S DISEASE; THROMBOANGIITIS OBLITERANS; THROMBOEMBOLISM; THROMBOPHLEBITIS; THROMBOSIS; VASODILATOR AGENTS
TRATTAMENTO FIBRINOLITICO E ANTICOAGULANTE INDIRETTO DELLA TROMBOSI.